Liver fibrosis - From bench to bedside

Journal of Hepatology, Supplement

Volumn 38, Issue 1, 2003, Pages

  Friedman, Scott L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CORTICOSTEROID; CYTOCHROME P450 2E1; CYTOCHROME P450 4A; CYTOKINE; GAMMA INTERFERON; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RETINOL; SCATTER FACTOR; THIAZOLIDINE DERIVATIVE; URSODEOXYCHOLIC ACID;

ALCOHOL LIVER DISEASE; APOPTOSIS; CELL ACTIVATION; CELL FATE; CELL PROLIFERATION; CHEMOTAXIS; CLINICAL FEATURE; CLINICAL TRIAL; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; EXTRACELLULAR MATRIX; FIBROGENESIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOMODULATION; LIVER BIOPSY; LIVER CELL; LIVER CIRRHOSIS; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; RETINOL DEFICIENCY; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; STEATOSIS; STELLATE CELL; ALCOHOL LIVER CIRRHOSIS; AUTOCRINE EFFECT; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; INFECTION COMPLICATION; KUPFFER CELL; LIVER FATTY DEGENERATION; LIVER INJURY; MEDICAL ASSESSMENT; MORPHOMETRICS; PARACRINE SIGNALING; PROTEIN PHOSPHORYLATION;

HUMANS; LIVER; LIVER CIRRHOSIS;

EID: 0037220482     PISSN: 01695185     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (149)

1. Friedman SL, editor. The hepatic stellate cell. Semin Liver Dis. New York, Vol 21. New York, NY: Thieme, 2001. pp. 307-452 P.D. Berk, series editor.
2. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-Beta in hepatic fibrosis. Front Biosci 2002;7:D793-D807.
3. Mann DA, Smart DE. Transcriptional regulation of hepatic stellate cell activation. Gut 2002;50:891-896.
4. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-472.
5. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000;160:3227-3230.
6. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002;122:1609-1619.
7. Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as modulator of stellate cell and hepatic fibrogenesis. Semin Liver Dis 2001;21:351-372.
8. Poynard T, Bedossa P, Opolon P, Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-832.
9. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-435.
10. Rosenberg W, Burt A, Becka M, Voelker M, Arthur MJP. Automated assays of serum markers of liver fibrosis predict histologic hepatic fibrosis. Hepatology 2000;32:183A.
11. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069-1075.
12. Schiano TD, Kim-Schluger L, Gondolesi G, Miller CM. Adult living donor liver transplantation: the hepatologist's perspective. Hepatology 2001;33:3-9.
13. Chen CH, Chen PJ, Chu JS, Yeh KH, Lai MY, Chen DS. Fibrosing cholestatic hepatitis in a hepatitis B surface antigen carrier after renal transplantation. Gastroenterology 1994;107:1514-1518.
14. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol 2001;34:730-739.
15. Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000;31:828-833.
16. Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, Liou A, et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001;34:283-287.
17. Shi Z, Wakil AE, Rockey DC. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Natl Acad Sci USA 1997;94:10663-10668.
18. Angelucci E, Muretto P, Nicolucci A, Baronciani D, Erer B, Gaziev J, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002;100:17-21.
19. Lagging LM, Westin J, Svensson E, Aires N, Dhillon AP, Lindh M, et al. Progression of fibrosis in untreated patients with hepatitis C virus infection. Liver 2002;22:136-144.
20. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-470.
21. Lindh M, Horal P, Dhillon AP, Norkrans G. Hepatitis B virus DNA levels precore mutations genotypes and histological activity in chronic hepatitis B. J Viral Hepat 2000;7:258-267.
22. Merican I, Guan R, Amarapuka D, Alexander MJ, Chutaputti A, Chien RN, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 2000;15:1356-1361.
23. Kobayashi M, Arase Y, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, et al. Clinical characteristics of patients infected with hepatitis B virus genotypes, A, B, and, C. J Gastroenterol 2002;37:35-39.
24. Lee HK, Yoon GS, Min KS, Jung YW, Lee YS, et al. Fibrosing cholestatic hepatitis: a report of three cases. J Korean Med Sci 2000;15:111-114.
25. Ozer E, Helvaci M, Yaprak I. Hepatic expression of viral antigens, hepatocytic proliferative activity and histologic changes in liver biopsies of children with chronic hepatitis B after interferon-alpha therapy. Liver 1999;19:369-374.
26. Kweon YO, Goodman ZD, Dienstag JL, Schiff ER, Brown NA, Burkhardt E, et al. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 2001;35:749-755.
27. Ruiz-Moreno M, Otero M, Millan A, Castillo I, Cabrerizo M, Jimenez FJ, et al. Clinical and histological outcome after hepatitis B e antigen to antibody seroconversion in children with chronic hepatitis B. Hepatology 1999;29:572-575.
28. Raynard B, Balian A, Fallik D, Capron F, Bedossa P, Chaput JC, et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002;35:635-638.
29. Nakano M, Worner TM, Lieber CS. Perivenular fibrosis in alcoholic liver injury: ultrastructure and histologic progression. Gastroenterology 1982;83:777-785.
30. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001;21:17-26.
31. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100.
32. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, et al. Liver fibrosis in overweight patients. Gastroenterology 2000;118:1117-1123.
33. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-1362.
34. Poynard T, McHutchison J, Manns M, Trepo C, Lindsey K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;123:1061-1069.
35. Hammel P, Couvelard A, O'Toole D, Ratouis A, Sauvanet A, Flejou JF, et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 2001;344:418-423.
36. Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 1997;127:981-985.
37. Iredale JP. Stellate cell behavior during resolution of liver injury. Semin Liver Dis 2001;21:427-436.
38. Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S, et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998;102:538-549.
39. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-524.
40. Arthur MJP. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. [Editorial]. Gastroenterology 2002;122(5):1525-1528.
41. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000;275:2247-2250.
42. Friedman SL, Maher JJ, Bissell DM. Mechanisms and therapy of hepatic fibrosis: report of the AASLD Single Topic Basic Research Conference. Hepatology 2000;32:1403-1408.
43. Geerts A. History and heterogeneity of stellate cells, and role in normal liver function. Semin Liver Dis 2001;21:311-336.
44. Cassiman D, van Pelt J, De Vos R, Van Lommel F, Desmet V, Yap SH, et al. Synaptophysin: a novel marker for human and rat hepatic stellate cells. Am J Pathol 1999;155:1831-1839.
45. Cassiman D, Libbrecht L, Desmet V, Denef C, Roskams T. Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J Hepatol 2002;36:200-209.
46. Dooley S, Streckert M, Delvoux B, Gressner AM. Expression of Smads during in vitro transdifferentiation of hepatic stellate cells to myofibroblasts. Biochem Biophys Res Commun 2001;283:554-562.
47. Dooley S, Delvoux B, Lahme B, Mangasser-Stephan K, Gressner AM. Modulation of transforming growth factor beta response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts. Hepatology 2000;31:1094-1106.
48. Gressner AM, Lotfi S, Gressner G, Haltner E, Kropf J. Synergism between hepatocytes and Kupffer cells in the activation of fat storing cells (perisinusoidal lipocytes). J Hepatol 1993;19:117-132.
49. Matsuoka M, Tsukamoto H. Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor beta: implication for a pathogenetic role in alcoholic liver fibrogenesis. Hepatology 1990;11:599-605.
50. Winwood PJ, Schuppan D, Iredale JP, Kawser CA, Docherty AJ, Arthur MJ. Kupffer cell-derived 95 kd type IV collagenase/gelatinase B: characterization and expression in cultured cells. Hepatology 1995;22:304-315.
51. Nieto N, Friedman SL, Greenwel P, Cederbaum AI. CYP2E1-mediated oxidative stress induces collagen type I expression in rat hepatic stellate cells. Hepatology 1999;30:987-996.
52. Nieto N, Friedman SL, Cederbaum AI. Cytochrome P450 2E1-derived reactive oxygen species mediate paracrine stimulation of collagen I protein synthesis by hepatic stellate cells. J Biol Chem 2002;277:9853-9864.
53. Casini A, Ceni E, Salzano R, Biondi P, Parola M, Galli A, et al. Neutrophil-derived superoxide anion induces lipid peroxidation and stimulates collagen synthesis in human hepatic stellate cells: role of nitric oxide. Hepatology 1997;25:361-367.
54. Schwabe RF, Schnabl B, Kweon YO, Brenner DA. CD40 activates NF-kappa B and c-Jun N-terminal kinase and enhances chemokine secretion on activated human hepatic stellate cells. J Immunol 2001;166:6812-6819.
55. Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001;34:738-744.
56. Rao MS, Reddy JK. Peroxisomal beta-oxidation and steatohepatitis. Semin Liver Dis 2001;21:43-55.
57. Marra F, Efsen E, Romanelli RG, Caligiuri A, Pastacaldi S, Batignani G, et al. Ligands of peroxisome-proliferator activated receptor gamma modulate profibrogenic and proinflammatory actions of hepatic stellate cells. Gastroenterology 2000;119(2):466-478.
58. Miyahara T, Schrum L, Rippe R, Xiong S, Yee Jr. HF, Motomura K, et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 2000;275:35715-35722.
59. Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G, et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002;122:1924-1940.
60. Neuschwander-Tetri BA. Evolving pathophysiologic concepts in nonalcoholic steatohepatitis. Curr Gastroenterol Rep 2002;4:31-36.
61. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-432.
62. Ikejima K, Honda H, Yoshikawa M, Hirose M, Kitamura T, Takei Y, et al. Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology 2001;34:288-297.
63. Honda H, Ikejima K, Hirose M, Yoshikawa M, Lang T, Enomoto N, et al. Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology 2002;36:12-21.
64. Leclercq IA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 2002;37:206-213.
65. Anania F. Leptin, liver and obese mice-fibrosis in the fat lane. Hepatology 2002;36:246-248.
66. Potter JJ, Womack L, Mezey E, Anania FA. Transdifferentiation of rat hepatic stellate cells results in leptin expression. Biochem Biophys Res Commun 1998;244:178-182.
67. Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 2002;35:762-771.
68. Olaso E, Friedman SL. Molecular mechanisms of hepatic fibrogenesis. J Hepatol 1998;29:836-847.
69. Pinzani M, Marra F. Cytokine receptors and signaling during stellate cell activation. Semin Liver Dis 2001;21:397-416.
70. Pinzani M, Milani S, Grappone C, Weber FJ, Gentilini P, Abboud HE. Expression of platelet-derived growth factor in a model of acute liver injury. Hepatology 1994;19:701-707.
71. Wong L, Yamasaki G, Johnson RJ, Friedman SL. Induction of beta-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J Clin Invest 1994;94:1563-1569.
72. Olaso E, Eng F, Lin C, Yancopoulous G, Friedman SL. The discoidin domain receptor 2 (DDR2) is induced during stellate cell activation, mediates cell growth and MMP2 expression, and is regulated by extracellular matrix. Hepatology 1999;30:413A.
73. Olaso E, Ikeda K, Eng FJ, Xu L, Wang L-H, Lin HC, et al. DDR2 receptor promotes MMP-2 mediated proliferation and invasion by hepatic stellate cells. J Clin Invest 2001;108(9):1369-1378.
74. Ikeda K, Wang LH, Torres R, Zhao H, Olaso E, Eng FJ, et al. Discoidin domain receptor 2 interacts with Src and Shc following its activation by type I collagen. J Biol Chem 2002;277:19206-19212.
75. Bachem MG, Riess U, Melchior R, Sell KM, Gressner AM. Transforming growth factors (TGF alpha and TGF beta 1) stimulate chondroitin sulfate and hyaluronate synthesis in cultured rat liver fat storing cells. FEBS Lett 1989;257:134-137.
76. Gressner AM. Cytokines and cellular crosstalk involved in the activation of fat-storing cells. J Hepatol 1995;22:28-36.
77. Bissell DM, Wang SS, Jarnagin WR, Roll FJ. Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation. J Clin Invest 1995;96:447-455.
78. Friedman SL, Yamasaki G, Wong L. Modulation of transforming growth factor beta receptors of rat lipocytes during the hepatic wound healing response. Enhanced binding and reduced gene expression accompany cellular activation in culture and in vivo. J Biol Chem 1994;269:10551-10558.
79. Schnabl B, Kweon YO, Frederick JP, Wang XF, Rippe RA, Brenner DA. The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology 2001;34:89-100.
80. Tahashi Y, Matsuzaki K, Date M, Yoshida K, Furukawa F, Sugano Y, et al. Differential regulation of autocrine TGFbeta signal in hepatic stellate cells between acute and chronic rat liver injury; implications regarding the role of SMADs in liver fibrosis. Hepatology 2002;35:49-61.
81. Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Fujimoto M, et al. Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J Invest Dermatol 1996;106:729-733.
82. Lasky JA, Ortiz LA, Tonthat B, Hoyle GW, Corti M, Athas G, et al. Connective tissue growth factor mRNA expression is upregulated in bleomycin-induced lung fibrosis. Am J Physiol 1998;275:L365-L371.
83. Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ, et al. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 1998;53:853-861.
84. Paradis V, Dargere D, Bonvoust F, Vidaud M, Segarini P, Bedossa P. Effects and regulation of connective tissue growth factor on hepatic stellate cells. Lab Invest 2002;82:767-774.
85. Paradis V, Dargere D, Vidaud M, De Gouville AC, Huet S, Martinez V, et al. Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology 1999;30:968-976.
86. Duncan MR, Frazier KS, Abramson S, Williams S, Klapper H, Huang X, et al. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP. FASEB J 1999;13:1774-1786.
87. Grotendorst GR. Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev 1997;8:171-179.
88. Rockey DC. Hepatic blood flow regulation by stellate cells in normal and injured liver. Semin Liver Dis 2001;21:337-350.
89. Racine-Samson L, Rockey DC, Bissell DM. The role of alpha1beta1 integrin in wound contraction. A quantitative analysis of liver myofibroblasts in vivo and in primary culture. J Biol Chem 1997;272:30911-30917.
90. Rockey DC, Chung JJ. Inducible nitric oxide synthase in rat hepatic lipocytes and the effect of nitric oxide on lipocyte contractility. J Clin Invest 1995;95:1199-1206.
91. Gupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 1998;28:926-931.
92. Gupta TK, Toruner M, Groszmann RJ. Intrahepatic modulation of portal pressure and its role in portal hypertension. Role of nitric oxide. Digestion 1998;59:413-415.
93. Groszmann RJ. Nitric oxide and hemodynamic impairment. Digestion 1998;59(Suppl 2):6-7.
94. Rockey DC. Cellular pathophysiology of portal hypertension and prospects for management with gene therapy. Clin Liver Dis 2001;5:851-865.
95. Friedman SL. Cytokines and fibrogenesis. Semin Liver Dis 1999;19:129-140.
96. Marra F, DeFranco R, Grappone C, Milani S, Pastacaldi S, Pinzani M, et al. Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol 1998;152:423-430.
97. Marra F, Valente AJ, Pinzani M, Abboud HE. Cultured human liver fat-storing cells produce monocyte chemotactic protein-1. Regulation by proinflammatory cytokines. J Clin Invest 1993;92:1674-1680.
98. Maher JJ, Lozier JS, Scott MK. Rat hepatic stellate cells produce cytokine-induced neutrophil chemoattractant in culture and in vivo. Am J Physiol 1998;275:G847-G853.
99. Wang SC, Tsukamoto H, Rippe RA, Schrum L, Ohata M. Expression of interleukin-10 by in vitro and in vivo activated hepatic stellate cells. J Biol Chem 1998;273:302-308.
100. Thompson KC, Trowern A, Fowell A, Marathe M, Haycock C, Arthur MJP, et al. Primary rat and mouse hepatic stellate cells express the macrophage inhibitor cytokine interleukin-10 during the course of activation In vitro. Hepatology 1998;28:1518-1524.
101. Thompson K, Maltby J, Fallowfield J, McAulay M, Millward-Sadler H, Sheron N. Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis. Hepatology 1998;28:1597-1606.
102. Louis H, Van Laethem JL, Wu W, Quertinmont E, Degraef C, Van den Berg K, et al. Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis induced by carbon tetrachloride in mice. Hepatology 1998;28:1607-1615.
103. Friedman SL. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993;328:1828-1835.
104. Okuno M, Sato T, Kitamoto T, Imai S, Kawada N, Suzuki Y, et al. Increased 9,13-di-cis-retinoic acid in rat hepatic fibrosis: implication for a potential link between retinoid loss and TGF-beta mediated fibrogenesis in vivo. J Hepatol 1999;30:1073-1080.
105. Gentilini A, Marra F, Gentilini P, Pinzani M. Phosphatidylinositol-3 kinase and extracellular signal-regulated kinase mediate the chemotactic and mitogenic effects of insulin-like growth factor-I in human hepatic stellate cells. J Hepatol 2000;32:227-234.
106. Tangkijvanich P, Tam SP, Yee Jr. HF. Wound-induced migration of rat hepatic stellate cells is modulated by endothelin-1 through rhokinase-mediated alterations in the acto-myosin cytoskeleton. Hepatology 2001;33:74-80.
107. Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Annu Rev Immunol 1997;15:675-705.
108. Marra F, Romanelli RG, Giannini C, Failli P, Pastacaldi S, Arrighi MC, et al. Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. Hepatology 1999;29:140-148.
109. Ikeda K, Wakahara T, Wang YQ, Kadoya H, Kawada N, Kaneda K. In vitro migratory potential of rat quiescent hepatic stellate cells and its augmentation by cell activation. Hepatology 1999;29:1760-1767.
110. Benyon D, Arthur MJP. Extracellular matrix degradation and the role of stellate cells. Semin Liver Dis 2001;21:373-384.
111. Iredale JP. Tissue inhibitors of metalloproteinases in liver fibrosis. Int J Biochem Cell Biol 1997;29:43-54.
112. Smart DE, Vincent KJ, Arthur MJ, Eickelberg O, Castellazzi M, Mann J, et al. JunD regulates transcription of the tissue inhibitor of metalloproteinases-1 and interleukin-6 genes in activated hepatic stellate cells. J Biol Chem 2001;276:24414-24421.
113. Trim JE, Samra SK, Arthur MJ, Wright MC, McAulay M, Beri R, et al. Upstream tissue inhibitor of metalloproteinases-1 (TIMP-1) element-1, a novel and essential regulatory DNA motif in the human TIMP-1 gene promoter, directly interacts with a 30 kDa nuclear protein. J Biol Chem 2000;275:6657-6663.
114. Friedman SL, Arthur MJ. Reversing hepatic fibrosis. Sci Med 2002;8:194-205.
115. Sohara N, Znoyko I, Levy MT, Trojanowska M, Reuben A. Reversal of activation of human myofibroblast-like cells by culture on a basement membrane-like substrate. J Hepatol 2002;37:214-221.
116. Issa R, Williams E, Trim N, Kendall T, Arthur MJ, Reichen J, et al. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut 2001;48:548-557.
117. Howard EW, Banda MJ. Binding of tissue inhibitor of metalloproteinases 2 to two distinct sites on human 72 kDa gelatinase. Identification of a stabilization site. J Biol Chem 1991;266:17972-17977.
118. Knittel T, Kobold D, Dudas J, Saile B, Ramadori G. Role of the Ets-1 transcription factor during activation of rat hepatic stellate cells in culture. Am J Pathol 1999;155:1841-1848.
119. Saile B, Knittel T, Matthes N, Schott P, Ramadori G. CD95/CD95L-mediated apoptosis of the hepatic stellate cell. A mechanism terminating uncontrolled hepatic stellate cell proliferation during hepatic tissue repair. Am J Pathol 1997:151:1265-1272.
120. Trim N, Morgan S, Evans M, Issa R, Fine D, Afford S, et al. Hepatic stellate cells express the low affinity nerve growth factor receptor p75 and undergo apoptosis in response to nerve growth factor stimulation. Am J Pathol 2000;156:1235-1243.
121. Preaux AM, D'Ortho MP, Bralet MP, Laperche Y, Mavier P. Apoptosis of human hepatic myofibroblasts promotes activation of matrix metalloproteinase-2. Hepatology 2002;36:615-622.
122. Murphy FR, Issa R, Zhou X, Ratnarajah S, Nagase H, Arthur MJ, et al. Inhibition of apoptosis of activated hepatic stellate cells by TIMP-1 is mediated via effects on MMP inhibition: implications for reversibility of liver fibrosis. J Biol Chem 2002;16:16.
123. Iwamoto H, Sakai H, Tada S, Nakamuta M, Nawata H. Induction of apoptosis in rat hepatic stellate cells by disruption of integrin-mediated cell adhesion. J Lab Clin Med 1999;134:83-89.
124. Wright MC, Issa R, Smart DE, Trim N, Murray GI, Primrose JN, et al. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 2001;121:685-698.
125. Bataller R, Brenner DA. Stellate cells as a target for treatment of liver fibrosis. Semin Liver Dis 2001;21:437-452.
126. Bissell DM, Maher JJ. Hepatic fibrosis and cirrhosis. In: Boyer TD, Zakim D, editors. Hepatology, a textbook of liver disease, 4th edition. London: Saunders, 2002. pp. 395-416.
127. Albanis E, Friedman SL. Hepatic fibrosis. Pathogenesis and principles of therapy. Clin Liver Dis 2001;5:315-334.
128. Angulo P, Batts KP, Therneau TM, Jorgensen RA, Dickson ER, Lindor KD. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999;29:644-647.
129. Kawada N, Seki S, Inoue M, Kuroki T. Effect of antioxidants, resveratrol, quercetin, and N-acetylcysteine, on the functions of cultured rat hepatic stellate cells and Kupffer cells. Hepatology 1998;27:1265-1274.
130. Houglum K, Venkataramani A, Lyche K, Chojkier M. A pilot study of the effects of D-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997;113:1069-1073.
131. Rockey DC, Chung JJ. Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implications for treatment of hepatic fibrosis. J Invest Med 1994;42:660-670.
132. Ueki T, Kaneda Y, Tsutsui H, Nakanishi K, Sawa Y, Morishita R, et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999;5:226-230.
133. Tahara M, Matsumoto K, Nukiwa T, Nakamura T. Hepatocyte growth factor leads to recovery from alcohol-induced fatty liver in rats. J Clin Invest 1999;103:313-320.
134. King Jr. TE. Interferon gamma-1b for the treatment of idiopathic pulmonary fibrosis. N Engl J Med 2000;342:974-975.
135. Kon K, Ikejima K, Hirose M, Yoshikawa M, Enomoto N, Kitamura T, et al. Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biophys Res Commun 2002;291:55-61.
136. Marra F, Efsen E, Romanelli RG, Caligiuri A, Pastacaldi S, Batignani G, et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000;119:466-478.
137. Geerts A, Rogiers V. Sho-saiko-To: the right blend of traditional oriental medicine and liver cell biology [editorial; comment]. Hepatology 1999;29:282-284.
138. Shimizu I, Ma YR, Mizobuchi Y, Liu F, Miura T, Nakai Y, et al. Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats [see comments]. Hepatology 1999;29:149-160.
139. Inoue T, Jackson EK. Strong antiproliferative effects of baicalein in cultured rat hepatic stellate cells. Eur J Pharmacol 1999;378:129-135.
140. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-1042.
141. Stefanovic B, Schnabl B, Brenner DA. Inhibition of collagen al(I) expression by the 5′ stem-loop as a molecular decoy. J Biol Chem 2002;11:11.
142. Okuno M, Akita K, Moriwaki H, Kawada N, Ikeda K, Kaneda K, et al. Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta. Gastroenterology 2001;120:1784-1800.
143. George J, Roulot D, Koteliansky VE, Bissell DM. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci USA 1999;96:12719-12724.
144. Arias M, Lahme B, Van De Leur E, Gressner AM, Weiskirchen R. Adenoviral delivery of an antisense RNA complementary to the 3′ coding sequence of transforming growth factor-beta1 inhibits fibrogenic activities of hepatic stellate cells. Cell Growth Differ 2002;13:265-273.
145. Rockey DC, Chung JJ. Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing. J Clin Invest 1996;98:1381-1388.
146. Yu Q, Shao R, Qian HS, George SE, Rockey DC. Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension. J Clin Invest 2000;105:741-748.
147. Pines M, Nagler A. Halofuginone: a novel antifibrotic therapy. Gen Pharmacol 1998;30:445-450.
148. Bruck R, Genina O, Aeed H, Alexiev R, Nagler A, Avni Y, et al. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology 2001;33:379-386.
149. Salgado S, Garcia J, Vera J, Siller F, Bueno M, Miranda A, et al. Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy. Mol Ther 2000;2:545-551.